Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab plus lenalidomide and dexamethasone retreatment in relapsed/refractory multiple myeloma
KCT0007076Phase 2
Key facts
- Status
- Recruiting
- Start
- Nov 2022
- Countries
- 1
- Sponsor
- Seoul St. Mary's Hospital
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Drugs
- daratumumab
- Conditions
- multiple myeloma (MM)
01
Overview
Phase 2, single-arm trial of daratumumab in multiple myeloma (MM), sponsored by Seoul St. Mary's Hospital. Started Nov 2022; status: recruiting.
02
Design
1 arm- Study design
- Non-randomizedSingle group
Daratumumab + lenalidomide + dexamethasone
Single treatment arm receiving combination of daratumumab with retreatment lenalidomide and dexamethasone for relapsed/refractory multiple myeloma.
03
Who it enrols
Adult patients with relapsed or refractory multiple myeloma who have been previously exposed to lenalidomide-based therapy. Evidence of disease progression after prior lenalidomide treatment is required.
Beyond the preview
Go deeper on KCT0007076.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0007076.